Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Maintenance treatment using abatacept with dose reduction after achievement of low disease activity in patients with rheumatoid arthritis (MATADOR) - A prospective, multicenter, single arm pilot clinical trial.
Yasuda S, Ohmura K, Kanazawa H, Kurita T, Kon Y, Ishii T, Fujieda Y, Jodo S, Tanimura K, Minami M, Izumiyama T, Matsumoto T, Amasaki Y, Suzuki Y, Kasahara H, Yamauchi N, Kato M, Kamishima T, Tsutsumi A, Takemori H, Koike T, Atsumi T. Yasuda S, et al. Among authors: matsumoto t. Mod Rheumatol. 2017 Nov;27(6):930-937. doi: 10.1080/14397595.2017.1286714. Epub 2017 Feb 16. Mod Rheumatol. 2017. PMID: 28150514 Clinical Trial.
The utility of 25-question Geriatric Locomotive Function Scale for evaluating functional ability and disease activity in Japanese rheumatoid arthritis patients: A cross-sectional study using NinJa database.
Izawa N, Hirose J, Fujii T, Oka H, Uehara K, Naito M, Matsumoto T, Tanaka S, Tohma S. Izawa N, et al. Among authors: matsumoto t. Mod Rheumatol. 2019 Mar;29(2):328-334. doi: 10.1080/14397595.2018.1457422. Epub 2018 Apr 18. Mod Rheumatol. 2019. PMID: 29575947
Does Abatacept Increase Postoperative Adverse Events in Rheumatoid Arthritis Compared with Conventional Synthetic Disease-modifying Drugs?
Ito H, Tsuji S, Nakayama M, Mochida Y, Nishida K, Ishikawa H, Kojima T, Matsumoto T, Kubota A, Mochizuki T, Sakuraba K, Matsushita I, Nakajima A, Hara R, Haraguchi A, Matsubara T, Kanbe K, Nakagawa N, Hamaguchi M, Momohara S; JOSRA Consortium. Ito H, et al. Among authors: matsumoto t. J Rheumatol. 2020 Apr;47(4):502-509. doi: 10.3899/jrheum.181100. Epub 2019 Jun 15. J Rheumatol. 2020. PMID: 31203226
10,262 results
You have reached the last available page of results. Please see the User Guide for more information.